Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
|Articles|March 1, 2003
No Frown Lines, No Tears
Birmingham, Ala. - In a rare occurrence, superficial punctate keratitis developed after injections of botulinum toxin type A to the glabellar area, a difficult diagnosis arrived at through the combined consultation of a dermatologist and an ophthalmologist.
Advertisement
Advertisement
Related to this article
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
5